Individualized and fine-tuned treatment
The medical company that has developed an innovative system for individualized dosing of tablets. Order MyFIDContact Us
About MyFID
MyFID is a programmable dosing device for tablets. By combining the possibilities of a modern technology and tablets with a smaller amount of active ingredients, a fine-tuned dosing can be achieved. By choosing a number of tablets a specific, individualized dose can be arrived.
MyFID is pre-programmed to deliver a certain amount of medicine at a certain time. The physician decides which dose a patient should use and when it should be taken. However in order for the device not to rule the user’s life, care has been taken to ensure that the user choose which functions of the device that should be active.
MyFID has unique registration capabilities. It registers the amount and time a dose is delivered. MyFID will ask and record reasons why a dose is taken. It also records disease symptoms using easy to use scales that allows for the patient and the doctor to follow treatment effects, to get a continuous picture of how the disease evolves and fluctuates with time.
All information recorded is available for both the user and the physician, and can be retrieved using an inbuilt standardized treatment report. MyFID therefore gives the physician and the patient a more precise and correct background for further treatment decisions.
Water-soluble tablets
Documented compliance
Effects in 20 minutes
Right dose at the right moment
Study 1
The first study was a so-called bioequivalence study, where the aim was to compare Sensidose’s own product, Flexilev® microtablets, with the same total dose of an existing drug product. This is a procedure that is common in the registration of generic drugs.
The aim of a bioequivalence study is to show that there is no significant difference in terms of absorption, distribution, metabolism or excretion of the active substance, what is also called pharmacokinetics. The drugs are given as single doses on one occasion, usually to healthy volunteers, under standardized conditions.
At predetermined points in time blood samples are drawn for analysis. In order for the substances to be considered bioequivalent, the rate of uptake as well as the degree of drug absorption and metabolism must be the same. If the tested product is bioequivalent with an already registered product, you can in principly apply for marketing approval of the new product.
Study 2
The rapid metabolism of levodopa is a problem for patients with Parkinson’s disease. In order to function normally they need to have a constant and individually adjusted plasma level of the drug. In this way a steady synthesis and availability of dopamine in the brain, with stable motor and psychomotor function is achieved. The drug Stalevo® contains levodopa and carbidopa, but also an inhibitor of the COMT enzyme and is considered to be the preparation in tablet form that best enables the desired steady supply of levodopa.
In a recently completed clinical study Flexilev was compared with Stalevo®. The study was a multiple dose, open, randomized, two-way crossover, phase I study in healthy volunteers.
Study 3
A recurring question is whether the results we obtained in healthy volunteers (see study 1) are applicable to patients with Parkinson’s disease in a more advanced phase. This study was conducted to answer this question. The study had two main objectives: 1) to investigate the pharmacokinetics (absorption, distribution, metabolism or excretion) of Flexilev in patients and 2) to monitor the effect of the dose by repeated examinations of motion with different measurement methods.
The study was a single dose, open, phase I study and was conducted at Uppsala University Hospital. 19 patients who had a average of 9.5 years duration of Parkinson’s disease participated in the study.
Study 4
Flexilev contains the same active ingredients as similar approved medicines. The difference is that treatment with Flexilev is individualized, ie the dose is adjusted according to each individual’s needs in steps of 5 mg. This accuracy in dosage can only be obtained with Flexilev. But is it effective? In this study, personalized treatment with Flexilev minitablets was compared to standard treatment.
The study was a four week open observational study conducted at the Sahlgrenska Hospital in Gothenburg. 24 patients participated and, on average, they had their Parkinson’s diagnosis for 9.5 years. To be able to participate in the study, the requirement was to take levodopa at least four times a day and have remaining symptoms. The study period was divided into two two-week periods. During the first, the participants received the same medication as before but given with Flexilev minitablets and the MyFID dosing device. However, the treatment itself was identical to that the patient had before the study. In the second two-week period, the dose was adjusted according to patient needs and in line with a motion measurement. Participants underwent the same type of tests before the study and after each of the two two-week intervals with different treatment.
Detailed product information for Flexilev is available here »
Latest news
Sensidose signs an agreement with Desitin Arzneimittel GmbH for sales and marketing of Flexilev/Suades in Germany
Sensidose AB (the "Company") has entered into a service agreement with Desitin Arzneimittel GmbH ("Desitin") for the sales and marketing of Flexilev (under the trade name Suades) in Germany. Sensidose and Desitin will share the revenue from the sales. The launch is...
Sensidose is awarded funding from Vinnova (Sweden´s Innovation Agency) to develop a method for objective registration and treatment of opiate-requiring pain conditions
Sensidose receives SEK 1.22 million in grants from Vinnova for industrial research within the call "Innovation projects in companies". The funding aims to support the company's development of measuring physiological reactions to pain to enable improved pain relief and...
Sensidose attended SALSS 2018 – All about Brains
Sensidose participated in the Swedish-American Life Science Summit (SALSS) between the 22nd to 24th of August 2018 in Stockholm, Sweden. The summit is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists,...
About Us
Sensidose AB is a pharmaceutical company that has developed a system for individualized dosing of pharmaceutical tablets, allowing for a fine tuned and patient centered drug therapy.
Contact Us
Sensidose AB
Vetenskapsvägen 10
191 38 Sollentuna, Sverige